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Background: An intention-to-treat analysis of randomized Bypass versus Angioplasty in Severe Ischaemia of the Leg
(BASIL) trial data showed that initial randomization to a bypass surgery (BSX)-first strategy was associated with
improvements in subsequent overall survival (OS) and amputation-free survival (AFS) of about 7 and 6 months,
respectively. We describe the nature and timing of first, crossover, and reinterventions and examine AFS and OS by first
treatment received. We also compare vein with prosthetic BSX and transluminal with subintimal balloon angioplasty
(BAP) and examine outcomes from BSX after failed BAP.
Methods:We randomly assigned 452 patients with SLI due to infrainguinal disease in 27 United Kingdom hospitals to a
BSX first (n 228) or a BAP first (n 224) revascularization strategy. All patients have been monitored for 3 years and
more than half for >5 years. We prospectively collected data on every procedure, major amputation, and death.
Results: Patients randomized to BAP were more likely to have their assigned treatment first (94% vs 85%, P .01, 2test).
BAP had a higher immediate technical failure rate of 20% vs 2.6% (P  .01, 2test). By 12 weeks after randomization 9
BAP (4%) vs 23 BSX (10%) patients had not undergone revascularization; 3 BAP (1.3%) vs 13 BSX (5.8%) had undergone
the opposite treatment first; and 35 BAP (15.6%) and 2 (0.9%) BSX had received the assigned treatment and then
undergone the opposite treatment. BSX distal anastomoses were divided approximately equally between the above and
below knee popliteal and crural arteries; most originated from the common femoral artery. About 25% of the grafts were
prosthetic and >90% of vein BSX used ipsilateral great saphenous vein. Most (80%) BAP patients underwent treatment
of the SFA alone (38%) or combined with the popliteal artery (42%) and crural arteries (20%). Outcome of vein BSX was
better for AFS (P  0.003) but not OS (P  0.38, log-rank tests) than prosthetic BSX. There were no differences in
outcome between approximately equal numbers of transluminal and subintimal BAP. AFS (P 0.006) but notOS (P 0.06,
log rank test) survival was significantly worse after BSX after failed BAP than after BSX as a first revascularization attempt.
Conclusions: BAP was associated with a significantly higher early failure rate than BSX. Most BAP patients ultimately required
surgery.BSXoutcomesafter failedBAPare significantlyworse than forBSXperformedasafirst revascularizationattempt.BSXwith
vein offers the best long termAFS andOS and, overall, BAP appears superior to prosthetic BSX. (J Vasc Surg 2010;51:18S-31S.)From Vascular Surgery, University of Birmingham and Vascular and Endo-
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18SSevere leg ischemia (SLI), characterized by rest/night
pain and tissue loss (ulceration, gangrene), leads to signif-
icant morbidity and mortality as well as to the consumption
of considerable health and social care resources in devel-
oped and developing countries.1 The Bypass versus Angio-
plasty in Severe Ischaemia of the Leg (BASIL) trial remains
the only multicenter, randomized controlled trial (RCT) to
have compared a bypass surgery (BSX)-first and a balloon
angioplasty (BAP)-first revascularization strategy for the
treatment SLI due to infrainguinal disease.
An intention-to-treat (ITT) analysis of the BASIL trial
has shown that BSX and BAP lead to similar amputation-
free survival (AFS) and overall survival (OS) out to 2 years
from randomization.2 However, for those patients who
survived for 2 years after intervention, initial randomiza-
tion to BSX was associated with a significant increase of 7.3
months in restricted mean OS and a nonsignificant increase
of 5.9 months in restricted mean AFS during the subse-
quent mean follow-up of 3.1 years (range, 1-7 years).3
Hospital costs and health-related quality of life (HRQOL)
were not significantly different between the two groups
during the first 3 years.4 These findings, based on an ITT
analysis of randomized data, suggest that patients expected
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whereas those not expected to survive 2 years should
normally be considered for BAP in the first instance.
Although most BASIL trial patients received their as-
signed treatment in a timely fashion, as was to be expected,
interventions were sometimes delayed, sometimes the op-
posite treatment was undertaken, and a small number of
patients received no revascularization for a variety of differ-
ent reasons. The rate of subsequent secondary and cross-
over interventions was also high, reflecting the complex
patient journeys often observed in the management of this
condition.
By-treatment-received (BTR) analyses of RCTs have to
be undertaken with very great care because the rigor of
randomization has been lost and a degree of bias is there-
fore inevitable. However, surgical and interventional col-
leagues have urged us strongly to undertake a BTR analysis
of the BASIL data. We recognize that such an approach is
appropriate, provided it is interpreted with caution, and
may increase the value of the trial to clinicians managing
these challenging patients. So, here we present an analysis
of the main clinical outcomes (AFS, OS) by the first inter-
vention received and describe the nature and timing of first,
crossover, and reinterventions. We also compare vein with
prosthetic BSX and transluminal with subintimal BAP and
examine outcomes from BSX after failed BAP.
METHODS
All patients who participated in this study provided
written informed consent. The study was approved by the
Multi-centre Research Ethics Committee (MREC) for
Scotland. The BASIL trial is registered with the National
Research Register (NRR) and the International Standard
Randomized Controlled Trials Number (ISRCTN) Scheme
(Number 45398889).
Trial methods. The BASIL trial methods have been
described in detail previously.2,3 Briefly, between August
1999 and June 2004, consultant vascular surgeons and
interventionalists in 27 United Kingdom (UK) hospitals
randomized 452 patients with SLI, defined as rest pain
and/or tissue loss (ulcer and/or gangrene) of arterial eti-
ology present for more than 2 weeks, and who on diagnos-
tic imaging had a pattern of disease which, in their joint
opinion, could equally well be treated by either infraingui-
nal BSX or BAP, to a BSX-first or a BAP-first revasculariza-
tion strategy. Responsible consultant vascular surgeons and
interventionalists were encouraged to undertake the as-
signed procedure as soon as possible after patient random-
ization; were permitted to use their normal custom and
practice with regard to preintervention assessment, the
intervention itself, and postintervention follow-up; and
were asked to record at the end of the procedure whether in
their view it had been an immediate technical success.
Data on all first and reinterventions were prospectively
collected, as were those on amputation of the trial limb at
the transtibial level or above, and death from any cause. For
the first year of follow-up, four dedicated research nurses
travelled regularly to trial centers to collect data on ran-domized patients. Thereafter, the data were collected lo-
cally by the vascular teams. The trial coordinator liaised
continually with these teams and travelled at least annually
to trial centers to collect data from paper-based and elec-
tronic hospital information systems on further procedures
and primary outcomes. Where necessary, we also contacted
primary care doctors and nurses. In addition, end point
data on deaths, amputations, and further procedures were
collected through national audit mechanisms.
Details of patients recruited in Scottish centers were
also logged with the Information and Statistics Division
(ISD) of the National Health Service in Scotland. All
patients alive at the end of follow-up had their status
confirmed by linkage to General Registry Office (Scotland)
or the Office of National Statistics England death records.
Hospital admissions for Scottish patients were obtained by
record linkage to Scottish Morbidity Records (SMR-01).
All patients have been followed-up for 3 years and more
than half for 5 years. Preintervention angiograms were
scored using the Bollinger system by a panel of surgeons
and radiologists blind to the treatment received and the
patient’s outcome.5,6
Statistical analysis. For the survival analyses, patients
with no report of survival were taken as censored at end
February 2007 if their death information was from ISD, at
end July 2007 if their death information was fromOffice of
National Statistics, or at the date of last clinical contact if it
was after this date. In addition, four patients who were lost
to follow-up and who were thought unlikely to have their
deaths recorded in the UK were censored at their last
follow-up times, all within 1 year 1 month of randomiza-
tion. Comparison of amputation-free survival and overall
survival was by log-rank tests. Other associations were
assessed by 2 and the Fisher exact test with tests for trend
where appropriate.
Role of the funding source. The sponsor of the study
(Health Technology Assessment, UK government fund-
ing) had no role in study design, data collection, data
analysis, data interpretation, or writing of the report.
Author declaration. The authors have had full access
to the data and take responsibility for its integrity; have read
and agree to the manuscript as written; and have no conflict
of interest to declare.
RESULTS
Nature and timing of first attempted revasculariza-
tion and subsequent procedures after randomization.
Of the 228 patients randomized to BSX first, 195 (85%)
underwent attempted surgery as their first procedure, and 5
underwent endarterectomy and vein patch rather than
BSX. Two bypasses were abandoned; one because the
surgeon considered the vessels were too calcified to con-
struct a distal anastomosis and one because the surgeon
could not find sufficient usable vein for a conduit and did
not want to use a prosthetic graft. In a further three
patients, a graft was inserted and the operation was com-
pleted, but in the opinion of the responsible consultant
surgeon undertaking the procedure, the bypass was not
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failure rate of 5 of 195 (2.6%). Thus, 193 patients (84%)
randomized to BSX underwent a completed surgical pro-
cedure as their first intervention, of which 188 were com-
pleted bypasses.2
Of the 224 patients randomized to BAP first, 216
(96%) underwent attempted BAP as their first procedure.
Of these, 43 (20%) of these were deemed immediate tech-
nical failures.2 In 10 patients this was because the vessel
lumen could not be entered or the disease could not be
completely crossed with a guidewire. The lesion was
crossed subintimally in 18 patients, but the lumen could
not be reentered. Two procedures were abandoned before
a guidewire had been passed across the disease because the
patient could not tolerate the procedure. Two procedures
were terminated because of vessel perforation after a guide-
wire had been passed. One procedure was terminated im-
mediately because the type of disease described as being
present in the preoperative duplex ultrasound image was
not present at the time of angiography. In a further 10
patients, there was immediate thrombosis of the BAP chan-
nel and in 6 there was also distal embolization that could
not be rectified radiologically by means of thrombolysis or
aspiration. All surgical and interventional procedures un-
dertaken on the trial leg at any time during follow-up
(range 3 to 7 years) are for the cohort as a whole and by trial
arm are reported in Table I.
The cumulative number of treatments received by pa-
tients during the first 12 weeks from randomization is
reported in Table II. By 12 weeks after randomization 9
(4%) BAP vs 23 (10%) BSX patients had not undergone
revascularization; 3 (1.3%) BAP vs 13 (5.8%) BSX had
undergone the opposite treatment first; and 35 (15.6%)
BAP and 2 (0.9%) BSX had received the assigned treatment
and then underwent the opposite treatment for immediate
technical or early clinical failure. Overall, 21 patients un-
derwent more than two attempts at revascularization dur-
ing the first 12 weeks after randomization. As the rate of
first attempted revascularization leveled off by the end of
week 8 after randomization, all subsequent BTR analyses
are presented using this 8 week cutoff.
Table III provides further details of all first and subse-
quent attempts at revascularization during the first 8 weeks
after randomization by randomized group, and the short-
term outcome of those attempted revascularizations and
the patient status of amputation or death at 8 weeks.
Surgery was attempted as a first revascularization procedure
8 weeks of randomization in 185 patients. BSX in 171
patients was immediately technically successful and no fur-
ther attempt at revascularization was undertaken during the
8 weeks after randomization or 30 days, whichever was
the longest. By 8 weeks, however, 12 of these 171 patients
had died and 4 had undergone major amputation of the
operated-on leg. BSX in three patients was judged an
immediate technical failure, one patient had no further
revascularization during the 8 weeks after randomization or
30 days, and two patients had further surgery during this
time period; one required an amputation within the8-week/30-day period. Eight patients had BSX as a first
revascularization that was judged to be an immediate tech-
nical success but went on to have BAP (7 patients) or
further surgery (1 patient) during the 8 weeks after ran-
domization or30 days. Two patients had BSX combined
with BAP as a technically successful first and only revascu-
larization during the first 8 weeks. Procedures and out-
comes in the 224 patients who underwent BAP as the first
attempted revascularization 8 weeks of randomization
can be gleaned from Table III in the same way.
Overall, in the first 8 weeks after randomization, pa-
tients randomized to BAP were more likely to have their
assigned treatment first (208 of 224 [93%] vs 182 of 228
[80%]; P  .01, 2 test) while those randomized to BSX
were more likely to have the opposite treatment first (16 of
228 [7.0%] vs 3 of 224 [1.3%]; P .04, Fisher exact test) or
no revascularization (30 of 228 [13.1%] vs 13 of 224
[5.8%]; P .01, Fisher exact test). The number of patients
assigned to BAP who did not receive their randomized
allocation as the first treatment was too small to make
comparisons with those that did. However, those that were
assigned to BSX and who did and did not receive surgery as
their first treatment were not different in terms of the five
baseline characteristics of age, below knee Bollinger angio-
Table I. All surgical and interventional procedures done
on the trial leg at any time during follow-up (range, 3-7
years)
Procedures
All
(n  452)
Randomization group
BAP BSX
(n  224) (n  228)
Revascularization
(interventional)
BAPa 299 243 56
BAP of graft stenosis 31 8 23
Stent 9 7 2
Revascularization (surgical)
BSX 266b 55 211
BSX and endarterectomy 6 4 2
Endarterectomy and vein
patch 7 2 5
Thromboembolectomy 31 17 14
Other 5 4 1
Amputations (major)
Above knee 40 19 21
Below knee 46 24 22
Minor procedures
Sympathectomy 6 2 4
Débridement 31 10 21
Other surgery 43 7 28
Skin graft 8 2 1
Amputations (minor)
Digital amputation 112 42 70
Forefoot amputation 14 5 9
BAP, Balloon angioplasty; BSX, bypass surgery.
aExcludes 2 cases where patient taken to the angiography suite but the
procedure was not attempted.
bExcludes 4 cases where patient taken to the operating theater but the
procedure was not attempted.gram score, presence of tissue loss, serum creatinine, num-
on or
he firs
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subsequent overall survival of the BASIL trial cohort as a
whole.7 A reason why the assigned BSX was not carried
out was recorded for 24 patients: death before surgery/
became unfit for BSX (13), no suitable vein (2), and
Table II. Cumulative treatments received 12 weeks afte
Treatment
Ra
1
No treatment 94
Randomized treatment only, immediate technical successb 104
Randomized treatment attempted and not done or
immediate technical failureb 19
Only opposite treatment, including immediate technical
failures 0
Randomized then opposite treatment, including
immediate technical failures 7
More than two revascularization attempts 0
All 224
BAP, Balloon angioplasty; BSF, bypass surgery.
aAs expected, the cumulative number of interventions increases gradually du
off by week 8 after randomization. For this reason, all subsequent analyses ha
8 weeks after randomization.
bImmediate technical success as judged by the responsible consultant surge
Table III. Revascularizations undertaken 8 weeks after
randomized group
First attempted
revascularization
All attempted revascularizations and
outcomesb
None None
BSX Taken to theatre but BSX not done
BSX, nil else
BSX combined with BAP, nil else
BSX, BAP
BSX, failed BAP
BSX, failed BAP, BAP
BSX, BSX
Failed BSX, nil else
Failed BSX, BSX
All BSX attempted first
BAP Taken to suite but BAP not done
BAP, nil else
BAP, BSX
BAP, BSX, BSX
BAP, BAP
BAP, failed BAP
Failed BAP, nil else
Failed BAP, failed BSX, BSX
Failed BAP, BSX
Failed BAP, failed BSX, failed BAP, BS
Failed BAP, BAP
All BAP attempted first
All Totals
BAP, Balloon angioplasty; BSX, bypass surgery.
aNumbers in brackets give the status at 8 weeks from randomization: A is a
bOutcomes in first 8 weeks after randomization: failed denotes immediat
revascularization procedure 8 weeks after randomization or 30 days of t
the first revascularization 8 weeks after randomization or 30 days.patient refused (9).Patients who had BAP as their first attempted revascu-
larization within the first 8 weeks were more likely to suffer
an immediate technical failure (as judged by the responsible
interventionalist at the time) or early clinical failure (re-
quirement for further revascularization procedure 8
domizationa
By end of week from randomization
ized to BAP (n  224) Randomized to BSX (n  228)
4 6 8 12 1 2 4 6 8 12
42 23 13 9 105 66 38 33 31 23
135 148 152 153 111 147 168 170 171 174
18 19 18 17 2 1 2 2 2 2
1 1 3 3 9 10 12 11 12 13
24 28 31 35 1 1 2 2 2 2
4 5 6 7 0 3 6 10 11 14
224 224 224 224 228 228 228 228 228 228
he time period in both arms. However, the rate of new interventions levels
mined amputation-free survival and overall survival by treatment(s) received
interventional radiologist.
mization by first intervention attempted and
Patient randomized toa
TotalBAP (n  224) BSX (n  228)
13 (A1, D1) 30 (D5) 43
1 (D1) 1
3 (D1) 168 (A4, D11) 171
2 2
4 4
2 2
1 1
1 (D1) 1
1 1
2 (A1) 2
3 (D1) 182 (A5, D13) 185
2 (A1) 2
153 (A4, D7) 11 (D1) 164
7 (A1) 7
1 (A1) 1
1 1
1 1
16 (A3, D2) 2 (A1) 18
1 1
24 (A1, D2) 2 26
1 (A1) 1
2 1 3
208 (A12, D11) 16 (A1, D1) 224
224 (A13, D13) 228 (A6, D19) 452
ith trial leg amputated at transtibial level or above; D is dead.
nical failure; nil else denotes immediate technical success and no further
t revascularization. Where other revascularizations are listed, these followedr ran
ndom
2
72
116
15
1
19
1
224
ring t
ve exarando
X
live w
e techweeks after randomization or 30 days, which ever was the
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first completed revascularization procedure during the first
8 weeks after randomization (14 of 185 [7.0%]; P  .001
2 test). In 42 of 60 (70%) patients, a failed first attempt at
BAP was followed by a further intervention and in 39 of 42
(93%) patients that was surgery (37 BSX). Those patients
that had successful and unsuccessful first attempted BAP
could not be distinguished by baseline characteristics that
predicated overall survival.6,7
Comparison of outcomes by treatment received in
first 8 week after randomization. As described above,
because the rate of first attempted revascularization leveled
off by the end of week 8 after randomization (Table II), the
treatments received up to that point were used to define
“on-treatment” groups. Specifically, patients were divided
into five groups by treatment(s) received in first 8 weeks
after randomization as follows:
1. Group 1: successful surgery only (n  173)
2. Group 2: successful BAP only (n  162)
3. Group 3: unsuccessful surgery, defined as immediate technical
failure or further intervention within the first 8 weeks or within
30 days of the procedure (n  11)
4. Group 4: unsuccessful BAP, defined as immediate technical
failure or further intervention within 8 weeks or 30 days
(n  60)
5. Group 5: no intervention in first 8 weeks (n  46)
Surgery groups (1 and 3). Four patients in group 1
and one patient in group 3 underwent endarterectomy and
vein patch rather than BSX (n 179). Details of the BSX in
group 1 (n 169) and group 3 (n 10) are given in Table
IV. Most BSX originated at the common femoral artery.
For the distal anastomosis, grafts were divided approxi-
mately equally between the above knee popliteal, below
knee popliteal, and crural arteries. With regard to the 56
infrapopliteal BSX, 14 were to the posterior tibial, 20 to the
anterior tibial, 18 to the peroneal artery, 14 were proximal
third, 16 were middle third, and 22 were distal third. There
were three dorsalis pedis grafts, one of which involved a
“stop-over” anastomosis to the below knee popliteal artery.
About one-quarter of the grafts involved the use of pros-
thetic material wholly or as a composite graft, with or
without a vein cuff. More than 90% of the vein BSX were
fashioned predominantly with ipsilateral great saphenous
vein.2 Because the number of unsuccessful BSX is small, it is
not possible to make any meaningful comparison between
those BSX that were successful and those that were not.
BAP groups (2 and 4). Describing often complex
attempts at BAP for severe multilevel disease in patients
with SLI is more difficult than describing BSX. We have
chosen to describe the BAP performed in groups 2 and 4 by
number of disease lengths treated (a disease length may
extend across several anatomic arterial segments) and the
number of anatomic arterial segments treated. With regard
to the former, although in 159 of 224 patients (72%)
interventionalists reported that they had attempted to treat
a single length of disease, in a substantial number of pa-tients it was reported that attempts had been made to treat
more than one (up to 4) separate disease lengths (Table V).
The numbers of reported transluminal (n  85) and sub-
intimal (n  97) BAP were approximately equal, with
about 15% BAP being reported as mixed. The pattern and
extent of anatomic segments treated was also complex
(Table VI). As expected, most patients underwent treat-
ment of the SFA (n  177) alone (n  68) or in combina-
tion with the popliteal artery (n  74) and (one or more)
crural arteries (n  32). Most of the remaining patients
underwent treatment of the popliteal segments alone or in
combination with crural arteries; the number of isolated
crural artery BAP was small. Despite the larger number of
unsuccessful BAP, as with the surgery groups, it does not
Table IV. Anatomic extent and type of bypass surgery
(BSX) in 179 patients undergoing a completed bypass as
their first attempted revascularization 8 weeks after
randomization (on treatment groups 1 and 3)
Bypass extent and type
Group 1
(n  169)
Group 3
(n  10)
All BSX
(n  179)
Successful
BSX
Unsuccessful
BSXa
No. No. No.
Proximal anastomosis
Common femoral artery 120 8 128
Superficial femoral artery 2 0 2
Above knee popliteal
artery 36 0 36
Below knee popliteal
artery 3 0 3
Previous graft 5 1 6
Tibioperoneal trunk 1 0 1
External iliac artery 2 0 2
Data not available 4 1 5
Distal anastomosis
Above knee popliteal
artery 58 2 60
Below knee popliteal
artery 61 2 63
Posterior tibial artery
Proximal third 2 0 2
Middle third 3 0 3
Distal third 8 1 9
Anterior tibial artery
Proximal third 5 1 6
Middle third 5 1 6
Distal third 7 1 8
Peroneal artery
Proximal third 5 1 6
Middle third 7 0 7
Distal third 4 1 5
Dorsalis Pedis 2 0 2
Tibioperoneal trunk 1 0 1
Dual popliteal and pedal 1 0 1
Conduit type
Vein 127 9 136
Prosthetic with cuffb 28 1 29
Prosthetic no cuffb 24 0 24
aUnsuccessful BSXmeans immediate technical failure or further intervention
8 weeks of randomisation or 30 days, whichever was longer.
bProsthetic grafts includes composite grafts.appear possible to easily distinguish successful and unsuc-
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treated, the type of BAP, or the anatomic segments
treated. Table VII reports the subsequent treatments
undertaken by the patients with failed primary proce-
dures (groups 3 and 4).
AFS andOS for these 5 on-treatment groups are shown
in Fig 1. AFS (P  .003, log-rank test) but not OS was
significantly worse in those patients who had a failed BAP
(group 4) than in those who had an initially successful BAP
(group 2). Neither AFS norOSwas significantly worse after
failed surgery (group 3 vs group 1); however, with only 11
failed cases, this comparison has very low power to detect
any difference. None of the other differences between
groups were significant. Those with no interventions in the
first 8 weeks had slightly poorer AFS and OS initially but
their long-term survival was somewhat better than those
who were treated successfully.
Vein versus prosthetic BSX. For group 1, we further
considered outcomes by whether vein (group 1a, n 127)
or prosthetic material (group 1b, n  42) was used as the
conduit for BSX. Patients receiving successful vein BSX as
their first and only treatment in the first 8 weeks after
randomization (group 1a) had better AFS (P  .003,
log-rank test) but not OS (P  .38, log-rank test) than
those receiving successful prosthetic bypasses as their first
and only treatment in the first 8 weeks (group 1b; Fig 2).
There was no significant association between the use of
prosthetic material for bypass and any of the baseline clin-
ical data.7
Transluminal vs subintimal BAP. For group 2, we
have further considered outcomes by whether the translu-
minal (group 2a, n 87) or subintimal (group 2b, n 75)
route was used for the first segment treated, as recorded at
the time by the responsible interventionalist, for BAP.
There were no differences in AFS or OS between translu-
Table V. Number of disease lengths treated and type by
balloon angioplasty (BAP) in 222 patients undergoing
attempted BAP as their first attempted revascularization
8 weeks after randomization (on treatment groups 2
and 4)
Variable
Group 2 (n  162) Group 4 (n  60)
Successful BAP only Unsuccessful BAPa
No. (%) No. (%)
Disease lengths treated,
No.
1 115 (71) 44 (73)
2 26 (16) 14 (24)
3 19 (12) 2 (3)
4 2 (1) . . .
Type of BAP
Transluminal 70 (43) 22 (37)
Subintimal 74 (46) 31 (52)
Mixed 18 (11) 7 (11)
aUnsuccessful BAP means immediate technical failure or further interven-
tion 8 weeks of randomization or 30 days, whichever was longer.minal and subintimal angioplasty (Fig 3).Results of BSX after failed BAP. Fig 4 compares AFS
and OS in patients who underwent BSX (whether initially
technically and/or clinically successful or not) after failed
BAP with all patients who underwent BSX (again whether
initially successful or not). The 37 patients in group 4 who
underwent BSX after first attempted failed angioplasty had
a poorer AFS (P  .006, log-ank test) and a somewhat
poorer OS (P .06, log-rank test) than the 184 patients in
groups 1 and 3 who underwent BSX as their first treatment.
DISCUSSION
The aim of the BASIL trial was to determine whether,
in patients with SLI due to infra-inguinal arterial disease, a
BSX first or a BAP first revascularization strategy was asso-
ciated with a better outcome in AFS, OS,HRQOL, and use
of hospital resources.
An ITT of randomized BASIL data showed there was
no significant difference between the two trial arms in AFS
or OS when the follow-up period was considered as a
whole.2 However, because of the changing relative hazards
of surgery and angioplasty over time, patients who survived
for 2 years and who were initially randomized to BSX
gained a significant 7 months of additional life and an
additional nonsignificant 6 months of amputation-free life
over the subsequent follow-up period from 2 years to 7
years 9 months after randomization.3
The purpose of the current analysis is to describe the
nature and timing of first, crossover, and reinterventions
received and the resulting AFS and OS. We also wished to
compare vein with prosthetic BSX and transluminal with
subintimal BAP and examine outcomes from BSX after
failed BAP.
Limitations of BTR analyses. BTR analyses of RCT
data must be undertaken and interpreted with great cau-
tion, and we have quite deliberately presented these in an
article separate from the ITT analysis.3 It is important to
appreciate that the validity of the conclusions and recom-
mendations that can be drawn from a preplanned ITT
statistical analysis of the randomized data from BASIL is
very much greater than that which can be drawn from the
present post hoc BTR analysis. With respect to BTR, bias is
unavoidable as a result of having lost the protection ran-
domization offers against such error.
Nevertheless, such analyses of the BASIL trial have
been widely requested by clinical colleagues, and if con-
ducted and interpreted transparently and appropriately, we
believe that they can provide useful additional insights into
the relative merits of the treatments being compared and
suggest further areas for research.
Such analyses are especially difficult to undertake in
patients that often have complex clinical journeys and mul-
tiple comorbidities, andwhere reintervention and crossover
intervention are common, especially in the period follow-
ing soon after randomization. Investigators have had to
make some decisions and assumptions to present what is
often a complex picture in a manner that is comprehensible
and clinically useful but at the same time does not over-
simplify the situation and so lead to erroneous conclusions
ow kn
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have been done in many different ways and not everyone
would have chosen to do it as we have done.
Timing of interventions: comparing strategies not
only procedures. Although almost all of the patients ran-
Table VI. Anatomic segments treated in 222 patients und
attempted revascularization 8 weeks after randomization
Anatomic segments treated
G
SFA  distal segments
SFA only
SFA  AKPA
SFA  AKPA  BKPA
SFA  AKPA  BKPA  Trifurcation
SFA  AKPA  BKPA  CA unspecified
SFA  AKPA  BKPA  PerA
SFA  AKPA  BKPA  ATA  PTA
SFA  AKPA  BKPA  ATA  PTA  PerA
Subtotal
AKPA / distal segments
AKPA only
AKPA  BKPA
AKPA  BKPA  CA unspecified
AKPA  BKPA  ATA  PTA
AKPA  BKPA  PerA
AKPA  BKPA  ATA  PTA  PerA
Subtotal
BKPA  distal segments
BKPA only
BKPA  Trifurcation
BKPA  CA unspecified
Sub-total
Crural arteries only
PerA only
ATA  PTA
Sub-total
Total
AKPA, Above knee popliteal artery; ATA, anterior tibial artery; BKPA, bel
tibial artery; SFA, superficial femoral artery.
Table VII. Further treatments after a failed primary
procedure (groups 3 and 4) 8 weeks from
randomization or 30 days after the primary intervention
Next treatment
Group 3
(n  11)
Group 4
(n  60)
Total
Unsuccessful
BSX
Unsuccessful
BAP
No. No. No.
No further treatment 1 12 13
BSX and endarterectomy 0 1 1
BSX 2 37 39
Endarterectomy 0 1 1
BAP 1 7 8
Stent 1 0 1
Chemical sympathectomy 0 1 1
Thromboembolectomy 6 1 7
Total 11 60 71
BAP, Balloon angioplasty; BSX, bypass surgery.domized in BASIL underwent an attempt at their allocatedtreatment fairly soon after randomization, as was to be
expected, some of those interventions were significantly
delayed, some of the first procedures were immediate tech-
nical or early clinical failures, some patients received the
opposite intervention first, and a small number of patients
received no attempt at revascularization at all.
It is important to re-emphasize that BASIL was not a
simple direct comparison of BAP vs BSX. Rather, it was a
comparison of a BSX-first with a BAP-first revascularization
strategy. Some commentators on BASIL have found that a
difficult distinction to understand and appreciate. How-
ever, it is a very important difference, because by comparing
strategies, we were able to compare not only the treatment
received, which may or may not have been the allocated
one, but also what happened before and after that treat-
ment.
With regard to what happens before the index proce-
dure, one advantage of choosing a BAP-first strategy ap-
pears to be that the patient is generally likely to be revascu-
larized more quickly. This may be because getting the
patient to the interventional suite for a 1-hour procedure
and then back to the main ward is logistically much easier
than getting them to an operating theatre for a 2 to 3 hour
ing attempted balloon angioplasty (BAP) as their first
treatment groups 2 and 4)
2 (n  162) Group 4 (n  60)
Totalessful BAP Unsuccessful BAP
o. (%) No. (%) No.
49 19 68
44 14 58
14 2 16
1 2 3
12 3 15
0 3 3
9 3 12
1 1 2
0 (80) 47 (78) 177
10 5 15
4 2 6
2 1 3
3 0 3
1 0 1
2 0 2
2 (14%) 8 (14%) 30
1 2 3
2 0 2
5 3 8
8 (5%) 5 (8%) 13
1 0 1
1 0 1
2 (1%) 0 (0%) 2
162 60 222
ee popliteal artery; CA, crural artery; PerA, peroneal artery; PTA, posteriorergo
(on
roup
Succ
N
13
2procedure and then back to a critical care bed. Or, it may be
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less workup than those destined for BSX.
With regard to events after the index procedure, we
expected BAP to be associated with a significant immediate
and early failure rate in this patient group, and we antici-
pated that a proportion of those patients would require
further, often surgical, procedures.8 With respect to sur-
gery, it was reasonable to expect the early failure rate would
be lower but that reinterventions, either angioplasty or
further open surgery, might be deemed necessary to main-
tain graft patency. These factors have to be offset against
the higher morbidity associated with BSX.2
By comparing strategies, we have been able to compare
not just individual index procedures but also a range of
other factors, some clinically driven and some logistical,
that in reality impact the complex journeys these patients
navigate before and after the first attempted revasculariza-
tion. Observational uncontrolled studies are not sensitive
to these sorts of important real-world influences; in reality,
they are difficult to perceive and quantify without the
confines of a RCT.
A small number of randomized patients were not revas-
Fig 1. A,Amputation-free survival and (B) overall survival for the
five treatment groups during follow-up.cularized either by BAP or, BSX. These patients exhibited aninitially poor survival but subsequently appeared to fare as well
as those undergoing revascularization. This is probably be-
cause the non-revascularized cohort comprised two quite
different groups of patients. First, there were those who
became too ill to undergo (or died before) surgery; and,
second, there were those whose symptoms improved with
best medical and nursing care to a point where they were no
longer deemed to require revascularization (or the patients
themselves withdrew consent). Two patients were not op-
erated on because the surgeon could not find a suitable vein
for bypass before surgery.
These data are in keeping with others who reported
surprisingly good outcomes with best medical and nursing
care alone even in patients with unreconstructable CLI.9
Physicians looking after this group of patients will recog-
nize that randomizing them to BSX or BAP, and then
ensuring that they undergo the assigned intervention in a
timely manner, requires a great deal of time spent with the
patient and the family. It is a great credit to the teams in
each of the 27 hospitals that about 70% of those invited to
take part in the trial accepted the offer; and that almost all of
them received their allocated treatment within a few weeks.
High rates of early BAP failure. Although patients
Fig 2. A, Amputation free survival and (B) overall survival for
patients undergoing bypass surgery according to type of bypass
conduit.were likely to receive BAP more quickly, the rate of imme-
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significantly higher than after BSX. As was to be expected,
most patients undergoing BAP within BASIL had severe,
multilevel disease.6 A review of the literature concerning
similar patients, not those with claudication and relatively
discrete disease, indicates that the BASIL data on immedi-
ate and early BAP failure are by no means atypical.10,11
Interventionalists will be keen to understand if there are any
factors that can be used to predict immediate and early BAP
failure in this patient group. Data on the perceived reasons
for immediate technical failure, as characterized by the
responsible interventionalist, are available and analyses of
these data in relation to clinical and angiographic patterns
of disease5,6 are on-going. However, present data show no
clear difference between successful and unsuccessful BAP in
extent, location, and type of BAP performed.
Results of BSX after failed BAP. It is often said,
although on the basis of little real evidence, that an unsuc-
cessful BAP does not jeopardize the chances of subsequent
BSX.12 In other words, apart from perhaps the cost, there is
“nothing to lose” by at least trying BAP first: if it works,
then all well and good, and if not, then proceed to BSX.13
Notwithstanding all the caveats surrounding BTR analyses,
the BASIL trial data do not appear to support this “free
Fig 3. A, Amputation free survival and (B) overall survival for
patients undergoing transluminal and subintimal angioplasty.shot” view of BAP.Patients with immediate or early BAP failure did signif-
icantly worse in terms of AFS even though most later had
apparently, at least initially, successful BSX. This may be
because failed BAP simply identifies a group of patients
who are going to do badly regardless of what surgical or
endovascular treatment is offered.7 Alternatively, it may be
that a failed BAP in some way jeopardizes the chances of
subsequent successful BSX in the longer term because it
affects the type and extent of BSX required or the run-off,
or both. By looking at the perceived causes of BAP failure,
comparing the characteristics of BSX undertaken as first
procedure with BSX undertaken after failed BAP, and by
looking at the causes of graft failure in those two groups, we
hope to be able to gain some further insight into mech-
anisms behind the present observation; this work is
on-going and will be the subject of a further report in
due course. For now, however, we can say that about
one-quarter of BAP for SLI are likely to fail immediately
(technically) or 8 weeks (clinically) and that, for rea-
sons as yet unclear, such patients will tend to do badly
even if they subsequently undergo an apparently initially
Fig 4. A, Amputation free survival and (B) overall survival in
patients randomized to and undergoing bypass surgery and in
patients undergoing bypass surgery after failed balloon angio-
plasty.successful BSX.
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current standard of care for SLI involves routine or “bail
out” stenting. Further, it has been suggested that if the trial
had been conducted in an era/health economy where
interventionalists had access to and chose to use modern
peripheral, possibly drug-eluting,14-20 stent (graft) tech-
nology, then results of the BASIL trial would have been
very different. There is no way of knowing whether this is
true. All we can really say with confidence is that the costs of
the interventional treatment would be much greater than
they were in BASIL where very few stents were placed.
However, a careful review of the most recently published
literature leads us to conclude that stenting (stent grafting)
may confer some benefit above the inguinal ligament and in
claudicant patients with limited disease of the superficial
femoral artery15,16,21,22 but that current evidence lends
little support to the idea that stenting in SLI patients with
extensive multilevel infrainguinal disease is likely to mean-
ingfully improve the overall clinical effectiveness above that
achieved by angioplasty alone.23
Looking at the BAP data presented here it is difficult for
us to believe that current stenting (stent graft) technology
would have materially improved overall outcomes in the
BAP arm of the trial. However, we are aware that others
may take a different view and that this is a rapidly develop-
ing field24 with new data on pharmacologic25,26 and pro-
cedural adjuvant techniques27 regularly entering the public
domain.28,29 Furthermore, going forward it is likely that
vascular specialists will increasingly want to exploit the
synergies to be enjoyed by combining surgical and endo-
vascular procedures in the same leg.30
Prosthetic bypass. The BASIL trial investigators have
been criticized for allowing the admission of prosthetic
bypasses and the trial participants for failing to be suffi-
ciently aggressive in using nonsaphenous venous conduit.
However, a review of the recent literature reveals a conflict-
ing view of the role of prosthetic bypass for this condition.
It is generally accepted that the results of prosthetic bypass
are worse than those constructed with vein and that the
difference in performance increases as the grafts become
more distal,31-34 but prosthetic grafts are still being widely
promoted, and one presumes used, for patients with SLI/
CLI.35,36 Various design modifications such as heparin
bonding37 and distal precuffing36,38 are claimed to be
effective in increasing graft patency to acceptable levels,
even for tibial bypasses.39,40 Others take the view that vein
should be used at all costs and that even high-risk nonsa-
phenous, spliced venous conduit is always preferable to a
prosthetic reconstruction.35,41
With regard to the BASIL trial, after considerable dis-
cussion and debate among the investigators and the partic-
ipants, the randomization was allowed of patients who
might require prosthetic bypass because in the UK (we
suspect the same was true in most other developed coun-
tries) at the time the trial was designed (1997-1998):
1. Femorodistal bypass using a prosthetic conduit, usually with a
venous cuff or boot below the knee, was a common operation.2. Vein bypass using nonsaphenous conduit was a less common
operation.
3. Preoperative veinmapping was not universally available or used,
and as a result, many patients would probably have been ran-
domized only to become a protocol violation when the surgeon
elected to use prosthetic rather than poor quality or nonsaphe-
nous vein during the surgery.
For these reasons, trial organizers strongly believed that
a vein bypass-only trial would be unable to recruit. A
three-way trial of BAP vs vein vs prosthetic BSX was briefly
mooted but quickly discounted for clinical, logistical, and
statistical reasons.
In the event, about one-quarter of the BSX undertaken
in the BASIL trial was constructed with prosthetic material
(either in whole or in part) and 90% of vein BSX were
predominantly constructed with ipsilateral great saphenous
vein.
Although nonrandomized, BTR analyses have to be
interpreted with great caution because of the risk of bias, it
does appear that in patients undergoing initially successful
BSX in the first 8 weeks after randomization, prosthetic
BSX performed very much less well in AFS, and to a lesser
extent OS, than vein BSX or (transluminal or subintimal)
angioplasty. There was no significant association between
the use of prosthetic material vs vein for bypass and any of
the predictive baseline clinical variables.7 So, this lack of
durability does not appear to be obviously due to the
selection for prosthetic bypass of higher-risk patients within
the group randomized to surgery; rather it appears to result
solely from a lack (in the opinion of the responsible sur-
geon) of suitable vein. So, although not randomized, we
believe the data offer reasonably convincing evidence for
the superiority of vein (predominantly saphenous) BSX
and, importantly, also BAP over prosthetic BSX in this
patient group.
Although one has to be very cautious when conflating
ITT2,3 and BTR analyses, we believe the overall BASIL trial
recommendation that patients likely to live 2 years after
intervention should usually have BSX rather than BAP
should be viewed in the context of the available bypass
conduit. Thus, it seems at least possible that had only those
patients able to undergo vein BSX been randomized in
BASIL, then the longer-term advantages of BSX over BAP
in terms of AFS, and possibly OS, would have been sub-
stantially greater than those actually observed because of
the inclusion within BASIL of a significant number of
generally very poorly performing prosthetic bypasses in the
BSX arm. It is also seems likely that many of the patients
who could not undergo a vein BSX would have been better
served by an attempt at BAP, where possible, rather than
prosthetic bypass in the first instance (even if their predicted
survival was2 years). The BASIL trial data reaffirms once
again that surgeons should make every effort to use vein
and to view prosthetic material in such patients as a last
resort; probably after BAP.
Choice of end points. AFS andOS were chosen as the
main clinical end points for BASIL because they are unam-
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years, there has been much discussion of end point selec-
tion and a trend towards using rather “softer,” nonclinical
(surrogate), composite end points. Several articles have
urged caution in the interpretation of such end points,
which can be manipulated to give the appearance of clinical
efficacy when none exists.23,42 The issue of end point
selection is considered at length elsewhere;3 suffice to say,
having presented the ITT analysis in terms of AFS and OS,
we think it is appropriate to restrict our BTR analysis to
those end points in this report.
AFS and OS after BSX and BAP are influenced by
comorbidity and not just the effectiveness of the revascu-
larization, and this makes applying the rigor of randomiza-
tion so powerful and important. The patients in the two
arms of the BASIL trial were not different in any clinically
important respect; as such, one can reasonably conclude
that any differences in outcome observed between the two
groups are the result of the two different strategies used.
Regrettably, and perhaps somewhat remarkably, the BASIL
trial remains the only RCT of surgical vs endovascular
treatment of infrainguinal disease for limb-threatening
ischemia.
Commentators on BASIL have also questioned the
wisdom of using OS as a major end point because limb
revascularization is not intended to improve long-term
survival. The prognosis of OS in patients with dysvascular
amputation is very poor. We think that by preserving the
limb, we also usefully extend life, although it would take an
RCT that randomizes to revascularization or primary am-
putation to know that for sure.
Some physicians have expressed surprise that we did not
use patency as major end point. This issue was discussed at
some length when the trial was designed in 1997 and 1998
and we actively decided not to use patency as an end point
for a number of clinical, scientific, and logistical reasons;
specifically:
First, patients are not concerned with patency but with
symptom relief (pain, wound healing), limb salvage and
preservation of life; we determined these should be the
primary end points.
Second, there is an imperfect relationship between patency
and these clinically important end points in these pa-
tients. Some patients experienced failure of their inter-
vention but no further reinterventions were required or
undertaken. Particularly in the group with rest pain
only (especially those with ankle pressures 50 mm
Hg) BAP, even BSX, may function as a temporary
bypass buying time for the leg/patient while collaterals
develop. So lives and legs can be lost with patent
grafts/endovascular procedures, while patients/legs
not infrequently often remain intact and pain-free after
the intervention has “failed” hemodynamically.
Third, assessing the patency of complex multisegment BAP
for multilevel disease in SLI patients in a standard and
reproducible manner is very difficult, perhaps impossi-
ble, especially across 27 centers.However, because AFS does not per se measure the
“quality” of revascularization, we collected measures of
HRQOL,3,4 hemodynamic data (ankle pressures), and in-
formation on relief of rest pain and healing of wounds and
minor amputations. These latter data are currently being
analyzed and will be the subject of a further separate report.
It has been suggested that we further analyze the data
using “amputation-and-reintervention-free” survival be-
cause reintervention is an important clinical event for the
patient and this composite end point might provide more
complete picture than AFS alone.
As discussed above, BTR analyses of RCTs are fraught
with methodologic challenges, especially when dealing
with patients that are subject to so many reinterventions
and crossover interventions. We have given very consider-
able thought about how to do this in a way that is sensible,
transparent, and clinically useful. We accept, however, that
regardless of how we choose to do this, our methods will
not find favor with everyone and that no method is perfect.
We have already explained why we chose to use AFS and
OS. With regard to reintervention, we have already de-
scribed both quantitatively and qualitatively the risks and
nature of re-interventions following both strategies in this
and other papers.2,3
The problem with using the suggested “amputation-
and-reintervention-free” survival is that it only accounts for
the first reintervention (which may not be the clinically
significant one). Also, some reinterventions are discretion-
ary, being based on hemodynamic and/or duplex ultra-
sound data rather than symptoms. For these reasons, we
have chosen to restrict our analyses to AFS and OS at this
stage, although wemay choose to report the trial according
to different end points in due course.
Nonstandard follow-up protocols and graft surveil-
lance. The trial has been criticized because it did notmandate
a specific postintervention follow-up regimen, which it
has been suggested should, at least for the bypass grafts,
have included routine duplex ultrasound-based surveil-
lance.
Once again, the BASIL trial must be viewed in the
context of what was considered usual practice in 1997 and
1998 when the trial was designed. At that time, at least in
the UK, duplex-based graft surveillance was not universally
used; indeed, not all surgeons are yet to be convinced that
it improves clinically important outcomes. The Vein Graft
Surveillance Randomized Trial (VGST), the RCT available,
concluded “intensive surveillance with duplex scanning did
not show any additional benefit in terms of limb salvage rates
for patients undergoing vein bypass graft operations, but it did
incur additional costs.” 43 So although there is a lot of expert
opinion in support of routine duplex ultrasound-based vein
graft surveillance,44 we are not aware of any level I evidence
that it is clinically effective or cost-effective. As stated
above, graft surveillance is an issue we are currently explor-
ing through on-going analyses in respect of the BASIL trial,
and we will report on that in due course in a further
manuscript.
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Although much has been said and written about the
relative merits of BSX and BAP in the treatment of
SLI,11,18,45-48 before BASIL, there was a complete ab-
sence of level I evidence from RCTs in the field. Like all
RCTs, BASIL is imperfect, but nevertheless, the investiga-
tors and participants believe it represents a useful compass
pointing the way toward evidence-based practice.49
Taking together (cautiously) the previous ITT2,3 and
the current BTR analyses, the overall recommendation
from BASIL is that SLI patients predicted to live2 years,
and with a useable vein, should usually have BSX first. This
is because the long-term results of saphenous vein BSX are
good, the rate of BAP failure is high, and results of BSX
after failed BAP are significantly worse than for primary
BSX. However, patients expected to live 2 years, and
those without a useable vein, should usually have BAP first
because they will not survive to reap the longer-term ben-
efits of surgery and the results of prosthetic BSX are poor.
The BASIL trial was only made possible by the enthu-
siasm and commitment of the trial centers and we thank all
the health care personnel in those centers for their support
of the study.
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APPENDIX
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